Compare Stocks: TNYA, PROK, ARVN, and TECX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARVN Arvinas	$8.81 -3.0%	$8.72	$6.97 ▼ $14.51	$568.10M	1.75	817,092 shs	418,535 shs
PROK ProKidney	$1.87 -6.3%	$1.68	$1.30 ▼ $3.48	$563.83M	1.7	1.02 million shs	762,062 shs
TECX Tectonic Therapeutic	$30.11 -0.9%	$32.99	$14.39 ▼ $39.53	$584.71M	3.31	264,591 shs	84,778 shs
TNYA Tenaya Therapeutics	$0.67 +0.8%	$0.76	$0.53 ▼ $2.35	$150.01M	2.77	3.49 million shs	899,958 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARVN Arvinas	-3.30%	-2.16%	+3.77%	+30.09%	+14.36%
PROK ProKidney	-1.00%	+7.57%	+21.34%	+19.16%	-7.87%
TECX Tectonic Therapeutic	-1.14%	-2.63%	-1.87%	+8.38%	+86.39%
TNYA Tenaya Therapeutics	-2.90%	-3.21%	-8.72%	-5.23%	-52.61%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARVN Arvinas	$8.81 -3.0%	$8.72	$6.97 ▼ $14.51	$568.10M	1.75	817,092 shs	418,535 shs
PROK ProKidney	$1.87 -6.3%	$1.68	$1.30 ▼ $3.48	$563.83M	1.7	1.02 million shs	762,062 shs
TECX Tectonic Therapeutic	$30.11 -0.9%	$32.99	$14.39 ▼ $39.53	$584.71M	3.31	264,591 shs	84,778 shs
TNYA Tenaya Therapeutics	$0.67 +0.8%	$0.76	$0.53 ▼ $2.35	$150.01M	2.77	3.49 million shs	899,958 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARVN Arvinas	-3.30%	-2.16%	+3.77%	+30.09%	+14.36%
PROK ProKidney	-1.00%	+7.57%	+21.34%	+19.16%	-7.87%
TECX Tectonic Therapeutic	-1.14%	-2.63%	-1.87%	+8.38%	+86.39%
TNYA Tenaya Therapeutics	-2.90%	-3.21%	-8.72%	-5.23%	-52.61%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARVN Arvinas	2.27	Hold	$14.17	60.89% Upside
PROK ProKidney	2.67	Moderate Buy	$12.00	543.43% Upside
TECX Tectonic Therapeutic	2.88	Moderate Buy	$77.25	156.53% Upside
TNYA Tenaya Therapeutics	2.86	Moderate Buy	$4.00	497.91% Upside

Current Analyst Ratings Breakdown

Latest TNYA, PROK, ARVN, and TECX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/3/2026	ARVN Arvinas	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
9/1/2026	TECX Tectonic Therapeutic	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
8/18/2026	TECX Tectonic Therapeutic	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/13/2026	ARVN Arvinas	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D)
8/10/2026	ARVN Arvinas	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$10.00
8/10/2026	ARVN Arvinas	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$14.00
8/10/2026	ARVN Arvinas	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$24.00 ➝ $21.00
8/7/2026	TECX Tectonic Therapeutic	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$101.00 ➝ $93.00
8/5/2026	ARVN Arvinas	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$11.00 ➝ $12.00
8/5/2026	ARVN Arvinas	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/4/2026	ARVN Arvinas	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$15.00 ➝ $11.00

(Data available from 9/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARVN Arvinas	$262.60M	2.16	N/A	N/A	$6.76 per share	1.30
PROK ProKidney	$818K	689.28	N/A	N/A	($3.36) per share	-0.56
TECX Tectonic Therapeutic	N/A	N/A	N/A	N/A	$13.43 per share	N/A
TNYA Tenaya Therapeutics	$1.34M	112.37	N/A	N/A	$0.57 per share	1.17

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARVN Arvinas	-$80.80M	$0.10	88.06	N/A	N/A	2.94%	1.91%	1.29%	11/4/2026 (Estimated)
PROK ProKidney	-$68.99M	-$0.55	N/A	N/A	N/A	-10,288.39%	N/A	-27.39%	11/9/2026 (Estimated)
TECX Tectonic Therapeutic	-$74.15M	-$4.57	N/A	N/A	N/A	N/A	-35.26%	-33.59%	11/5/2026 (Estimated)
TNYA Tenaya Therapeutics	-$90.60M	-$0.53	N/A	N/A	N/A	N/A	-83.75%	-66.53%	11/11/2026 (Estimated)

Latest TNYA, PROK, ARVN, and TECX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	PROK ProKidney	-$0.14	-$0.15	-$0.01	-$0.15	$0.19 million	$0.15 million
8/6/2026	Q2 2026	TECX Tectonic Therapeutic	-$1.35	-$1.18	+$0.17	-$1.18	N/A	N/A
8/5/2026	Q2 2026	TNYA Tenaya Therapeutics	-$0.0683	-$0.20	-$0.1317	-$0.20	$10.00 million	$1.11 million
8/4/2026	Q2 2026	ARVN Arvinas	-$0.3741	$2.58	+$2.9541	$2.58	$60.71 million	$249.70 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARVN Arvinas	N/A	N/A	N/A	N/A	N/A
PROK ProKidney	N/A	N/A	N/A	N/A	N/A
TECX Tectonic Therapeutic	N/A	N/A	N/A	N/A	N/A
TNYA Tenaya Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARVN Arvinas	N/A	7.91	7.91
PROK ProKidney	N/A	8.36	8.36
TECX Tectonic Therapeutic	N/A	22.29	22.29
TNYA Tenaya Therapeutics	N/A	4.52	4.52

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARVN Arvinas	95.19%
PROK ProKidney	51.59%
TECX Tectonic Therapeutic	62.63%
TNYA Tenaya Therapeutics	90.54%

Insider Ownership

Company	Insider Ownership
ARVN Arvinas	7.30%
PROK ProKidney	39.83%
TECX Tectonic Therapeutic	39.80%
TNYA Tenaya Therapeutics	2.53%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARVN Arvinas	420	64.52 million	59.81 million	Optionable
PROK ProKidney	3	302.32 million	181.91 million	Optionable
TECX Tectonic Therapeutic	120	19.55 million	11.77 million	N/A
TNYA Tenaya Therapeutics	110	224.23 million	218.56 million	Optionable

TNYA, PROK, ARVN, and TECX Headlines

Recent News About These Companies

BlackRock Inc. Acquires New Stake in Tenaya Therapeutics, Inc. $TNYA

September 6 at 3:36 AM | marketbeat.com

Tenaya Therapeutics (NASDAQ:TNYA) Upgraded at Wall Street Zen

September 6 at 1:13 AM | americanbankingnews.com

Wall Street Zen Upgrades Tenaya Therapeutics (NASDAQ:TNYA) to Sell

September 6 at 1:11 AM | marketbeat.com

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

September 5, 2026 | marketbeat.com

Tenaya Therapeutics to Participate in Upcoming September Investor Conferences

September 3, 2026 | globenewswire.com

Tenaya Therapeutics (NASDAQ:TNYA) Stock Rating Lowered by Wall Street Zen

August 29, 2026 | americanbankingnews.com

Tenaya Therapeutics (NASDAQ:TNYA) Cut to Strong Sell at Wall Street Zen

August 29, 2026 | marketbeat.com

1,555,500 Shares in Tenaya Therapeutics, Inc. $TNYA Purchased by ADAR1 Capital Management LLC

August 26, 2026 | marketbeat.com

Empery Asset Management LP Takes $2.86 Billion Position in Tenaya Therapeutics, Inc. $TNYA

August 22, 2026 | marketbeat.com

Faraz Ali Sells 22,232 Shares of Tenaya Therapeutics (NASDAQ:TNYA) Stock

August 18, 2026 | insidertrades.com

Tenaya Therapeutics Eyes Q4 Updates for Cardiac Gene Therapies, TN-301

August 18, 2026 | marketbeat.com

Tenaya Therapeutics (NASDAQ:TNYA) CEO Sells $15,784.72 in Stock

August 17, 2026 | marketbeat.com

GSA Capital Partners LLP Makes New $1.97 Million Investment in Tenaya Therapeutics, Inc. $TNYA

August 17, 2026 | marketbeat.com

Tenaya Therapeutics, Inc. (TNYA) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript

August 14, 2026 | seekingalpha.com

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Average Recommendation of "Moderate Buy" by Brokerages

August 11, 2026 | marketbeat.com

Renaissance Technologies LLC Increases Stock Holdings in Tenaya Therapeutics, Inc. $TNYA

August 10, 2026 | marketbeat.com

HC Wainwright Has Positive Outlook of TNYA FY2026 Earnings

August 10, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (TNYA) and Viridian Therapeutics (VRDN)

August 7, 2026 | theglobeandmail.com

Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

August 5, 2026 | globenewswire.com

Tenaya Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference

August 4, 2026 | globenewswire.com

Cours Tenaya Therapeutics, Inc.

July 29, 2026 | zonebourse.comZ

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNYA, PROK, ARVN, and TECX Company Descriptions

Arvinas NASDAQ:ARVN

$8.80 -0.28 (-3.03%)

As of 02:54 PM Eastern

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

ProKidney NASDAQ:PROK

$1.86 -0.13 (-6.28%)

As of 02:54 PM Eastern

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Tectonic Therapeutic NASDAQ:TECX

$30.11 -0.29 (-0.94%)

As of 02:55 PM Eastern

Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.

Tenaya Therapeutics NASDAQ:TNYA

$0.67 +0.01 (+0.84%)

As of 02:54 PM Eastern

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TNYA, PROK, ARVN, and TECX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TNYA, PROK, ARVN, and TECX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TNYA, PROK, ARVN, and TECX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNYA, PROK, ARVN, and TECX Company Descriptions

Arvinas NASDAQ:ARVN

ProKidney NASDAQ:PROK

Tectonic Therapeutic NASDAQ:TECX

Tenaya Therapeutics NASDAQ:TNYA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TNYA, PROK, ARVN, and TECX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TNYA, PROK, ARVN, and TECX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TNYA, PROK, ARVN, and TECX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNYA, PROK, ARVN, and TECX Company Descriptions

Arvinas NASDAQ:ARVN

ProKidney NASDAQ:PROK

Tectonic Therapeutic NASDAQ:TECX

Tenaya Therapeutics NASDAQ:TNYA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools